secwatch.observer — SEC 8-K summary
======================================

Issuer:     Liquidia Corp (LQDA)
CIK:        0001819576
Form:       8-K
Filed at:   2022-12-05T23:59:59+00:00
Accession:  0001104659-22-124592
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Liquidia collaborates with Sandoz and Mainbridge to develop new pump for treprostinil; promotion deal extended to 2032
--------------------------------------------------------------------------------

- Development agreement with Mainbridge to create new subcutaneous pump for treprostinil injection, targeting 510(k) submission in 2023.
- Sandoz and Liquidia will equally split development costs; Mainbridge to perform all development, validation, and testing.
- Promotion agreement for Treprostinil Injection extended by five years, now through December 31, 2032.
- New pump aims to reduce single-source dependence on existing CADD-MS 3 system for PAH patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819576/000110465922124592/0001104659-22-124592-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819576/000110465922124592/tm2231990d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-124592

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer